Literature DB >> 21237172

Site-specific coupling and sterically controlled formation of multimeric antibody fab fragments with unnatural amino acids.

Benjamin M Hutchins1, Stephanie A Kazane, Karin Staflin, Jane S Forsyth, Brunhilde Felding-Habermann, Peter G Schultz, Vaughn V Smider.   

Abstract

Immunoconjugates and multispecific antibodies are rapidly emerging as highly potent experimental therapeutics against cancer. We have developed a method to incorporate an unnatural amino acid, p-acetylphenylalanine (pAcPhe) into an antibody antigen binding fragment (Fab) targeting HER2 (human epidermal growth factor receptor 2), allowing site-specific labeling without disrupting antigen binding. Expression levels of the pAcPhe-containing proteins were comparable to that of wild-type protein in shake-flask and fermentation preparations. The pAcPhe-Fabs were labeled by reaction with hydroxylamine dye and biotin species to produce well-defined, singly conjugated Fabs. We then coupled a hydroxylamine biotin to the pAcPhe-Fab and demonstrated controlled assembly of Fabs in the presence of the tetrameric biotin-binding protein, NeutrAvidin. The position of Fab biotinylation dictates the geometry of multimer assembly, producing unique multimeric Fab structures. These assembled Fab multimers differentially attenuate Her2 phosphorylation in breast cancer cells that overexpress the Her2 receptor. Thus, an encoded unnatural amino acid produces a chemical "handle" by which immunoconjugates and multimers can be engineered.
Copyright © 2011. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21237172      PMCID: PMC4278757          DOI: 10.1016/j.jmb.2011.01.011

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  23 in total

1.  Design, construction, and in vitro analyses of multivalent antibodies.

Authors:  Kathy Miller; Gloria Meng; Jun Liu; Amy Hurst; Vanessa Hsei; Wai-Lee Wong; Rene Ekert; David Lawrence; Steven Sherwood; Laura DeForge; Jacques Gaudreault; Gilbert Keller; Mark Sliwkowski; Avi Ashkenazi; Leonard Presta
Journal:  J Immunol       Date:  2003-05-01       Impact factor: 5.422

2.  A genetically encoded boronate-containing amino acid.

Authors:  Eric Brustad; Mark L Bushey; Jae Wook Lee; Dan Groff; Wenshe Liu; Peter G Schultz
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

3.  Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.

Authors:  Ian E Krop; Muralidhar Beeram; Shanu Modi; Suzanne F Jones; Scott N Holden; Wei Yu; Sandhya Girish; Jay Tibbitts; Joo-Hee Yi; Mark X Sliwkowski; Fred Jacobson; Stuart G Lutzker; Howard A Burris
Journal:  J Clin Oncol       Date:  2010-04-26       Impact factor: 44.544

4.  Site-specific PEGylation of proteins containing unnatural amino acids.

Authors:  Alexander Deiters; T Ashton Cropp; Daniel Summerer; Mridul Mukherji; Peter G Schultz
Journal:  Bioorg Med Chem Lett       Date:  2004-12-06       Impact factor: 2.823

5.  A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy.

Authors:  J Schultz; Y Lin; J Sanderson; Y Zuo; D Stone; R Mallett; S Wilbert; D Axworthy
Journal:  Cancer Res       Date:  2000-12-01       Impact factor: 12.701

6.  Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.

Authors:  Hyun-Soo Cho; Karen Mason; Kasra X Ramyar; Ann Marie Stanley; Sandra B Gabelli; Dan W Denney; Daniel J Leahy
Journal:  Nature       Date:  2003-02-13       Impact factor: 49.962

7.  Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.

Authors:  Ralf Bargou; Eugen Leo; Gerhard Zugmaier; Matthias Klinger; Mariele Goebeler; Stefan Knop; Richard Noppeney; Andreas Viardot; Georg Hess; Martin Schuler; Hermann Einsele; Christian Brandl; Andreas Wolf; Petra Kirchinger; Petra Klappers; Margit Schmidt; Gert Riethmüller; Carsten Reinhardt; Patrick A Baeuerle; Peter Kufer
Journal:  Science       Date:  2008-08-15       Impact factor: 47.728

8.  Addition of the keto functional group to the genetic code of Escherichia coli.

Authors:  Lei Wang; Zhiwen Zhang; Ansgar Brock; Peter G Schultz
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-23       Impact factor: 11.205

9.  High level Escherichia coli expression and production of a bivalent humanized antibody fragment.

Authors:  P Carter; R F Kelley; M L Rodrigues; B Snedecor; M Covarrubias; M D Velligan; W L Wong; A M Rowland; C E Kotts; M E Carver
Journal:  Biotechnology (N Y)       Date:  1992-02

10.  Three-dimensional structure of the tetragonal crystal form of egg-white avidin in its functional complex with biotin at 2.7 A resolution.

Authors:  L Pugliese; A Coda; M Malcovati; M Bolognesi
Journal:  J Mol Biol       Date:  1993-06-05       Impact factor: 5.469

View more
  27 in total

1.  Synthesis of bispecific antibodies using genetically encoded unnatural amino acids.

Authors:  Chan Hyuk Kim; Jun Y Axup; Anna Dubrovska; Stephanie A Kazane; Benjamin A Hutchins; Erik D Wold; Vaughn V Smider; Peter G Schultz
Journal:  J Am Chem Soc       Date:  2012-06-06       Impact factor: 15.419

2.  Bispecific small molecule-antibody conjugate targeting prostate cancer.

Authors:  Chan Hyuk Kim; Jun Y Axup; Brian R Lawson; Hwayoung Yun; Virginie Tardif; Sei Hyun Choi; Quan Zhou; Anna Dubrovska; Sandra L Biroc; Robin Marsden; Jason Pinstaff; Vaughn V Smider; Peter G Schultz
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-14       Impact factor: 11.205

Review 3.  Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry.

Authors:  Jessica R McCombs; Shawn C Owen
Journal:  AAPS J       Date:  2015-01-22       Impact factor: 4.009

Review 4.  Site-Specifically Labeled Immunoconjugates for Molecular Imaging--Part 2: Peptide Tags and Unnatural Amino Acids.

Authors:  Pierre Adumeau; Sai Kiran Sharma; Colleen Brent; Brian M Zeglis
Journal:  Mol Imaging Biol       Date:  2016-04       Impact factor: 3.488

5.  Genetic Incorporation of the Unnatural Amino Acid p-Acetyl Phenylalanine into Proteins for Site-Directed Spin Labeling.

Authors:  Eric G B Evans; Glenn L Millhauser
Journal:  Methods Enzymol       Date:  2015-07-02       Impact factor: 1.600

Review 6.  Therapeutic applications of an expanded genetic code.

Authors:  Sophie B Sun; Peter G Schultz; Chan Hyuk Kim
Journal:  Chembiochem       Date:  2014-07-18       Impact factor: 3.164

7.  Site-specific DNA-antibody conjugates for specific and sensitive immuno-PCR.

Authors:  Stephanie A Kazane; Devin Sok; Edward H Cho; Maria Loressa Uson; Peter Kuhn; Peter G Schultz; Vaughn V Smider
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-15       Impact factor: 11.205

Review 8.  Improving theranostics in pancreatic cancer.

Authors:  Jeremy King; Michael Bouvet; Gagandeep Singh; John Williams
Journal:  J Surg Oncol       Date:  2017-05-17       Impact factor: 3.454

9.  Multiformat T-cell-engaging bispecific antibodies targeting human breast cancers.

Authors:  Yu Cao; Jun Y Axup; Jennifer S Y Ma; Rongsheng E Wang; Seihyun Choi; Virginie Tardif; Reyna K V Lim; Holly M Pugh; Brian R Lawson; Gus Welzel; Stephanie A Kazane; Ying Sun; Feng Tian; Shailaja Srinagesh; Tsotne Javahishvili; Peter G Schultz; Chan Hyuk Kim
Journal:  Angew Chem Int Ed Engl       Date:  2015-04-27       Impact factor: 15.336

10.  Synthesis and Incorporation of Unnatural Amino Acids To Probe and Optimize Protein Bioconjugations.

Authors:  Johnathan C Maza; Jaclyn R McKenna; Benjamin K Raliski; Matthew T Freedman; Douglas D Young
Journal:  Bioconjug Chem       Date:  2015-08-21       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.